Palliative radiation therapy for non-small cell lung cancer.
The palliative treatment of patients with NSCLC should be individualized. Treatment decisions should be directed by the goal of maximizing the patient's quality of life, and the patient's wishes should always be ascertained. The approaches to palliative radiation treatment of the chest, bones, and brain are quite similar. Treatment of the chest and bones is usually reserved until symptoms are significant. Brain metastases are generally treated soon after diagnosis. With respect to dose-fractionation schedules, the data are not conclusive. In theory, more protracted schedules of 40 to 50 Gy in 4 to 5 weeks are associated with more durable responses and less long-term morbidity than are shorter and lower-dose schedules. These regimens are therefore worth considering for the most favorable subset of palliative patients (i.e., those with good performance status and low burden of disease). At the other end of the spectrum, very ill patients with poor performance status may be best served by short hypofractionated schedules such as 20 Gy in five fractions, 17 Gy in two fractions, or possibly 8 to 10 Gy in one fraction. Response rates with these regimens are good, trips to the treatment facility are minimized, and these ill patients will probably not live long enough to experience the higher long-term toxicity rates associated with larger treatment fractions. The majority of patients, however, fall between these two extremes and are well served by schedules such as 30 Gy in 10 fractions. Radiation treatment fields should not be excessive but cover gross disease with a limited margin. (In the setting of brain metastases, treatment of the whole brain is recommended.) Further study of palliative treatment approaches should focus not only on assessments of response and toxicity but also on the impact of different treatments on overall quality of life.
Baldini
E H
EH
Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts, USA.
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy*